Latest news and press releases about Jazz Pharmaceuticals plc (JAZZ): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymph...
Price
| Price | $236.04 |
| Market Cap | $14.8B |
| Exchange | NASDAQ |
| Country | IE |
Valuation Ratios
| P/E Ratio | 15.50 |
| Price / Book | 3.10 |
| EV / EBITDA | 132.76 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -8.25% |
| Return on Invested Capital | 1.22% |
| Return on Assets | -3.05% |
| Gross Margin | 84.67% |
| Operating Margin | 31.05% |
| Net Margin | 20.45% |
Related companies: ABVX · AXSM · CAI · CYTK · HALO · MDGL · MRUS
Explore sector: Healthcare · Biotechnology
More sections of JAZZ: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks